Regorafenib for treatment of imatinib- and sunitinib-resistant metastatic gastrointestinal stromal tumors

References

• Barnett CM, Corless CL, Heinrich MC. Gastrointestinal stromal tumors: molecular markers and genetic subtypes. Hematol Oncol Clin North Am. 2013;27:871–888. doi:10.1016/j.hoc.2013.07.003.
   PubMed Web of Science ®Google Scholar
• Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer. 2011;11:865–878. doi:10.1038/nrc3143.
   PubMed Web of Science ®Google Scholar
• Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006;130:1466–1478.
   PubMed Web of Science ®Google Scholar
• Nilsson B, Bumming P, Jm M-K, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era. Cancer. 2005;103:821–829.
   PubMed Web of Science ®Google Scholar
• Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577–580.
   PubMed Web of Science ®Google Scholar
• Kindblom LG, Remotti HE, Aldenborg F, et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998;152:1259–1269.
   PubMed Web of Science ®Google Scholar
• Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol. 1983;7:507–519.
   PubMed Web of Science ®Google Scholar
• Rubin BP, Singer S, Tsao C, et al. KIT Activation Is a Ubiquitous Feature of Gastrointestinal Stromal Tumors. Cancer Res. 2001;61:8118–8121.
   PubMed Web of Science ®Google Scholar
• Edmonson JH, Marks RS, Buckner JC, et al. Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Cancer Invest. 2002;20:605–612.
   PubMed Web of Science ®Google Scholar
• DeMatteo RP, Heinrich MC, El-Rifai W, et al. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol. 2002;33:466–477.
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Griffith DJ, Druker BJ, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000;96:925–932.
   PubMed Web of Science ®Google Scholar
• Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344:1052–1056.
   PubMed Web of Science ®Google Scholar
• Demetri GD, Von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–480.
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299:708–710.
   PubMed Web of Science ®Google Scholar
• Pantaleo MA, Astolfi A, Indio V, et al. SDHA loss-of-function mutations in KIT-PDGFRA wild-type gastrointestinal stromal tumors identified by massively parallel sequencing. J Natl Cancer Inst. 2011;103:983–987. doi:10.1093/jnci/djr130.
   PubMed Web of Science ®Google Scholar
• Nannini M, Astolfi A, Urbini M, et al. Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST). BMC Cancer. 2014;14:685. doi:10.1186/1471-2407-14-685.
   PubMed Web of Science ®Google Scholar
• Joensuu H, Vehtari A, Riihimaki J, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol. 2012;13:265–274. doi:10.1016/S1470-2045(11)70299-6.
   PubMed Web of Science ®Google Scholar
• Joensuu H, Eriksson M, Sundby HK, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012;307:1265–1272. doi:10.1001/jama.2012.347.
   PubMed Web of Science ®Google Scholar
• Reichardt P, Blay JY, Boukovinas I, et al. Adjuvant therapy in primary GIST: state-of-the-art. Ann Oncol. 2012;23:2776–2781. doi:10.1093/annonc/mds198.
   PubMed Web of Science ®Google Scholar
• DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231:51–58.
   PubMed Web of Science ®Google Scholar
• Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008;26:626–632.
   PubMed Web of Science ®Google Scholar
• Van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet. 2001;358:1421–1423.
   PubMed Web of Science ®Google Scholar
• Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364:1127–1134.
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21:4342–4349. doi:10.1200/JCO.2003.04.190.
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol. 2006;24:4764–4774. doi:10.1200/JCO.2006.06.2265.
   PubMed Web of Science ®Google Scholar
• Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res. 2005;11:4182–4190.
   PubMed Web of Science ®Google Scholar
• Debiec-Rychter M, Cools J, Dumez H, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology. 2005;128:270–279. S0016508504020311[pii].
   PubMed Web of Science ®Google Scholar
• Liegl B, Kepten I, Le C, et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol. 2008;216:64–74.
   PubMed Web of Science ®Google Scholar
• Wardelmann E, Merkelbach-Bruse S, Pauls K, et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res. 2006;12:1743–1749.
   PubMed Web of Science ®Google Scholar
• Joensuu H, Eriksson M, Sundby HK, et al. Adjuvant imatinib for high-risk gi stromal tumor: analysis of a randomized trial. J Clin Oncol. 2016;34:244–250. doi:10.1200/JCO.2015.62.9170.
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Maki RG, Corless CL, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008;26:5352–5359.
   PubMed Web of Science ®Google Scholar
• Demetri GD, Van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329–1338.
   PubMed Web of Science ®Google Scholar
• Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9:327–337.
   PubMed Web of Science ®Google Scholar
• Sun L, Liang C, Shirazian S, et al. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2003;46:1116–1119.
   PubMed Web of Science ®Google Scholar
• Gajiwala KS, Wu JC, Christensen J, et al. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci U S A. 2009;106:1542–1547. doi:10.1073/pnas.0812413106.
   PubMed Web of Science ®Google Scholar
• Demetri GD, Heinrich MC, Fletcher JA, et al. Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res. 2009;15:5902–5909. doi:10.1158/1078-0432.CCR-09-0482.
   PubMed Web of Science ®Google Scholar
• Garner AP, Gozgit JM, Anjum R, et al. Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients. Clin Cancer Res. 2014;20:5745–5755. doi:10.1158/1078-0432.CCR-14-1397.
   PubMed Web of Science ®Google Scholar
• Kang YK, Ryu MH, Yoo C, et al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2013;14:1175–1182. doi:10.1016/S1470-2045(13)70453-4.
   PubMed Web of Science ®Google Scholar
• Reichardt P, Blay J, Gelderblom H, et al. Phase III trial of nilotinib in patients with advanced gastrointestinal stromal tumor (GIST): First results from ENEST g3. J Clin Oncol. 2010;28:15s(suppl; abstr 10017).
   Google Scholar
• Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099–7109. doi:10.1158/0008-5472.CAN-04-1443.
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129:245–255. doi:10.1002/ijc.25864.
   PubMed Web of Science ®Google Scholar
• Folkman J, Merler E, Abernathy C, et al. Isolation of a tumor factor responsible for angiogenesis. J Exp Med. 1971;133:275–288.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353–364. S0092-8674(00)80108-7[pii].
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–134. doi:10.1056/NEJMoa060655.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390. doi:10.1056/NEJMoa0708857.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–124. doi:10.1056/NEJMoa065044.
   PubMed Web of Science ®Google Scholar
• Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501–513. doi:10.1056/NEJMoa1003825.
   PubMed Web of Science ®Google Scholar
• Ryan CW. Dosing strategies and optimization of targeted therapy in advanced renal cell carcinoma. J Oncol Pharm Pract. 2015. doi:10.1177/1078155215618769.
   PubMedGoogle Scholar
• Schmieder R, Hoffmann J, Becker M, et al. Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer. Int J Cancer. 2014;135:1487–1496. doi:10.1002/ijc.28669.
   PubMed Web of Science ®Google Scholar
• Abou-Elkacem L, Arns S, Brix G, et al. Regorafenib inhibits growth, angiogenesis and metastasis in a highly aggressive, orthotopic colon cancer model. Mol Cancer Ther. 2013. doi:10.1158/1535-7163.MCT-12-1162.
   PubMed Web of Science ®Google Scholar
• Huynh H, Ong R, Zopf D. Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer. J Exp Clin Cancer Res. 2015;34:132. doi:10.1186/s13046-015-0243-5.
   PubMed Web of Science ®Google Scholar
• Dumas J, Hatoum-Mokdad H, Sibley R, et al. 1-Phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitors. Bioorg Med Chem Lett. 2000;10:2051–2054. S0960-894X(00)00272-9[pii].
   PubMed Web of Science ®Google Scholar
• Boyer S, Dumas J, Riedl B, et al. Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions. 8,637,553. 2014 Jan 28.
   Google Scholar
• Mross K, Frost A, Steinbild S, et al. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res. 2012;18:2658–2667. doi:10.1158/1078-0432.CCR-11-1900.
   PubMed Web of Science ®Google Scholar
• Strumberg D, Scheulen ME, Schultheis B, et al. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. Br J Cancer. 2012;106:1722–1727. doi:10.1038/bjc.2012.153.
   PubMed Web of Science ®Google Scholar
• Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol. 2009;10:992–1000. doi:10.1016/S1470-2045(09)70240-2.
   PubMed Web of Science ®Google Scholar
• Wong AL, Lim JS, Sinha A, et al. Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib. J Transl Med. 2015;13:57. doi:10.1186/s12967-015-0405-4.
   PubMed Web of Science ®Google Scholar
• George S, Wang Q, Heinrich MC, et al. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol. 2012;30:2401–2407. doi:10.1200/JCO.2011.39.9394.
   PubMed Web of Science ®Google Scholar
• Tlemsani C, Huillard O, Arrondeau J, et al. Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib. Expert Opin Drug Metab Toxicol. 2015;11:785–794. doi:10.1517/17425255.2015.1030392.
   PubMed Web of Science ®Google Scholar
• Highlights of prescribing information. 2016. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf
   Google Scholar
• George S, Feng Y, Von Mehren M, et al. Prolonged survival and disease control in the academic phase II trial of regorafenib in GIST: Response based on genotype. J Clin Oncol. 2013;31:suppl; abstract 10511.
   Web of Science ®Google Scholar
• Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:295–302. doi:10.1016/S0140-6736(12)61857-1.
   PubMed Web of Science ®Google Scholar
• Kollàr A, Maruzzo M, Messiou C, et al. Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program. Clin Sarcoma Res. 2014;4:17. doi:10.1186/2045-3329-4-17.
   PubMedGoogle Scholar
• Komatsu Y, Doi T, Sawaki A, et al. Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial. Int J Clin Oncol. 2015;20:905–912. doi:10.1007/s10147-015-0790-y.
   PubMed Web of Science ®Google Scholar
• Grothey A, Van CE, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303–312. doi:10.1016/S0140-6736(12)61900-X.
   PubMed Web of Science ®Google Scholar
• Li J, Qin S, Xu R, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16:619–629. doi:10.1016/S1470-2045(15)70156-7.
   PubMed Web of Science ®Google Scholar
• Eisen T, Joensuu H, Nathan PD, et al. Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. Lancet Oncol. 2012;13:1055–1062. doi:10.1016/S1470-2045(12)70364-9.
   PubMed Web of Science ®Google Scholar
• Mir O, Brodowicz T, Wallet J, et al. Activity of regorafenib (RE) in leiomyosarcomas (LMS) and other types of soft-tissue sarcomas (OTS): Results of a double-blind, randomized placebo (PL) controlled phase II trial. J Clin Oncol. 2015;33:Suppl; abstract 10504.
   PubMed Web of Science ®Google Scholar
• FDA approves stivarga for GIST. Cancer Discov. 2013Mar;27(3):164. doi:10.1158/2159-8290.CD-NB2013-039.
   Google Scholar
• Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol. 2005;23:3502–3508. doi:10.1200/JCO.2005.10.017.
   PubMed Web of Science ®Google Scholar
• Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol. 2008;26:3523–3529. doi:10.1200/JCO.2007.15.4138.
   PubMed Web of Science ®Google Scholar
• Hurwitz HI, Yi J, Ince W, et al. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist. 2009;14:22–28. doi:10.1634/theoncologist.2008-0213.
   PubMed Web of Science ®Google Scholar
• Grothey A, Allegra C. Antiangiogenesis therapy in the treatment of metastatic colorectal cancer. Ther Adv Med Oncol. 2012;4:301–319. doi:10.1177/1758834012454464.
   PubMed Web of Science ®Google Scholar
• Joulain F, Proskorovsky I, Allegra C, et al. Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer. Br J Cancer. 2013;109:1735–1743. doi:10.1038/bjc.2013.523.
   PubMed Web of Science ®Google Scholar
• Van CE, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30:3499–3506. doi:10.1200/JCO.2012.42.8201.
   PubMed Web of Science ®Google Scholar
• Davis SL, Eckhardt SG, Messersmith WA, et al. The development of regorafenib and its current and potential future role in cancer therapy. Drugs Today (Barc). 2013;49:105–115. doi:10.1358/dot.2013.49.2.1930525.
   PubMed Web of Science ®Google Scholar
• Jonasch E, Motzer RJ. Ten years of progress in renal cell carcinoma. J Natl Compr Canc Netw. 2012;10:690–693. 10/6/690 [pii].
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Jonasch E, Agarwal N, et al. Kidney cancer, version 3.2015. J Natl Compr Canc Netw. 2015;13:151–159. 13/2/151 [pii].
   PubMedGoogle Scholar
• Brodowicz T, Liegl-Atzwager B, Tresch E, et al. Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial. BMC Cancer. 2015;15:127. doi:10.1186/s12885-015-1143-y.
   PubMed Web of Science ®Google Scholar
• Mir O, Brodowicz T, Wallet J, et al. Activity of regorafenib (RE) in leiomyosarcomas (LMS) and other types of soft-tissue sarcomas (OTS): results of a double-blind, randomized placebo (PL) controlled phase II trial. J Clin Oncol. 2015;33:Suppl; abstract 10504.
   PubMed Web of Science ®Google Scholar
• Jones RL, Bendell JC, Smith DC, et al. A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer. Cancer Chemother Pharmacol. 2015;76:777–784. doi:10.1007/s00280-015-2827-3.
   PubMed Web of Science ®Google Scholar
• Report on the deliberation results. 2016. Available from: http://www.pmda.go.jp/files/000153351.pdf#page=1.
   Google Scholar
• Weinstein IB. Cancer. Addiction to oncogenes–the Achilles heal of cancer. Science. 2002;297:63–64. doi:10.1126/science.1073096.
   PubMed Web of Science ®Google Scholar